SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amidst an "unprecedented" memory shortage, fueled by surging AI demand for High-Bandwidth Memory (HBM) that experts project will persist into 2027. The community is highly optimistic, highlighting Micron's unique position as the sole U.S. HBM producer, its relatively low valuation, and recent analyst upgrades. This strong bullish sentiment is reinforced by news of significant manufacturing expansions and a substantial insider share purchase.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending due to reports of China blocking shipments of its H200 AI chips, coupled with broader market uncertainty from escalating international trade tensions. While some investors anticipate market turbulence, a strong bullish contingent emphasizes NVIDIA's entrenched AI leadership and robust demand for its next-generation Blackwell and Rubin platforms, viewing current dips as prime buying opportunities.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is currently trending due to a sharp price drop and heightened volatility, fueled by recent critical reports and ongoing speculation of market manipulation. Despite the downturn, community discussions highlight conviction in its robust AI-powered ad platform and anticipate a rebound, particularly with upcoming earnings expected to showcase strong fundamentals.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is actively trending amid intense community debate surrounding its tokenomics and upcoming developments. While some express concern over perceived continuous coin minting impacting supply, others are highly optimistic about the proposed 'Mission 70' initiative, designed to significantly reduce inflation. This comes as the community anticipates key Web3 events, positioning ICP as a foundational layer for decentralized cloud and AI applications, with many expecting significant adoption news.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept Inc. (VERO) is trending following the disclosure that a single institutional shareholder now controls 91% of the company's shares, creating an extremely tight public float. This has spurred a heated debate among investors, with many anticipating an unprecedented short squeeze and significant price appreciation due to the limited tradable shares. Conversely, a vocal group warns of a potential pump-and-dump, highlighting the company's underlying fundamentals and the risk of delisting at a low valuation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock as investors eagerly await its upcoming earnings report, with community perspectives sharply divided on whether the company will deliver a strong rebound from oversold conditions. A significant talking point revolves around the ongoing Warner Bros. Discovery acquisition saga, with bulls seeing it as a growth catalyst and bears concerned about its financial impact. Recent disclosures regarding bond purchases by a prominent political figure in both Netflix and Warner Bros. Discovery further add to the market's mixed sentiment and speculation surrounding the deal's future.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending intensely following Saudi Arabia's groundbreaking approval of its Anktiva treatment for lung cancer, marking the first global nod for this non-chemo combination, alongside significant progress in its AI-driven NK cell manufacturing. This development, amplified by Dr. Patrick Soon-Shiong's direct public engagement, is fueling widespread community excitement about a potential paradigm shift in oncology and fervent speculation regarding a short squeeze amidst high market interest. Investors and patients alike are discussing the implications of international regulatory confidence and the company's efforts to revolutionize cancer treatment accessibility and cost, putting immense pressure on traditional pharmaceutical and regulatory landscapes.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is actively discussed amidst renewed concerns over potential US tariffs on European economies related to Greenland, which has prompted caution in European markets and the bond sector. This geopolitical tension has sharply divided the community, with many anticipating a significant market pullback, while a strong counter-narrative expects a swift "buy the dip" recovery based on historical resilience to similar events.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors anticipate an upcoming business update call, which follows a major joint venture with a Saudi industrial conglomerate securing 100% offtake for its Greenland rare earth production. The community is buzzing with discussion around Greenland's strategic importance for critical minerals, intensified by geopolitical developments highlighting the need for secure supply chains. This confluence of news positions CRML as a central focus for those seeking exposure to the crucial rare earths sector.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

The United States Natural Gas Fund (UNG) is trending due to forecasts predicting an intense cold snap across large parts of the US, which is expected to significantly boost heating demand. Community sentiment is largely divided between those anticipating a major short squeeze and a sustained rally, possibly fueled by growing energy needs for AI data centers, and those remaining wary of natural gas's notorious volatility and strong production levels that could temper further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stephens Investment Management Group LLC Purchases Shares of 1,599,668 Travere Therapeutics, Inc. $TVTX

Stephens Investment Management Group LLC purchased a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the third quarter, according to its most recent disclosure...

Mirum Stock Rises 7% in a Week: Here's What You Should Know

MIRM shares rise this week on strong preliminary 2025 sales, upbeat 2026 outlook,  key pipeline goals and business updates.

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information...

Equities Analysts Issue Forecasts for TVTX FY2030 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Travere Therapeutics in a report issued on Wednesday, January 14th. HC...

TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA

Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.

<ul class="summary-bullets"><li>The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit.</li><li>The company submitted responses and the agency determined that the responses constitute a major amendment to the application.&nbsp;</li><li>The FDA is now expected to decide on the application by April 13, 2026.</li></ul>Shares of Travere Therapeutics, Inc., (TVTX) traded 19% lower on Tuesday after the company announced that U.S. Food and Drug Administration (FDA) has extended the review timeline for its application seeking approval of Filspari in focal segmental glomerulosclerosis.The FDA is now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-FDA-Extends-Review-of-sNDA-for-FILSPARI-sparsentan-in-FSGS/default.aspx">expected</a> to decide on the application by April 13, 2026. The agency was initially expected to rule on the application by Jan. 13.<h2 class="st-heading-2">Why The Delay?</h2>The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline, the company said. The agency requested no additional information on the safety or manufacturing of Filspari, it added.According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. FSGS is a kidney disease causing sclerosis, or scarring in some filters of the kidneys, leading to protein leakage, swelling, and potentially kidney failure.CEO Eric Dube said that the company remains committed to working with the FDA during the extension period and making preparations for a potential commercial launch.Filspari is also approved by the FDA to slow kidney function decline in adults with IgA nephropathy, a chronic autoimmune kidney disease where deposits of the immunoglobulin A (IgA) antibody build up in the kidney's filters, causing inflammation, scarring, and damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TVTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the FDA would eventually reject the drug.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/641686497</stembedurl>Another opined that the FDA wouldn’t have extended the review timeline if it was planning on a rejection.<stembedurl>https://www.stocktwits.com/apux/message/641686139</stembedurl><a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> has gained 48% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 

Equity

According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 


Travere Therapeutics, Sony And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<ul class="summary-bullets"><li>Travere said its responses are currently under agency review.</li><li>FDA’s PDUFA target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis is January 13.</li><li>The company expects U.S. net product sales of about $127 million in Q4 and about $410 million for the full year 2025.</li></ul>Shares of Travere Therapeutics Inc.&nbsp;(TVTX) slumped 30% in premarket trading on Tuesday after the company said the U.S. Food and Drug Administration (FDA) requested additional information to assess Filspari’s clinical benefit.Travere said its responses are currently under agency review. Filspari is a treatment for adults with primary immunoglobulin A nephropathy, a progressive kidney disease that can ultimately lead to kidney failure.FDA’s PDUFA (Prescription Drug User Fee Act) target action date for full approval of Filspari in Focal Segmental Glomerulosclerosis (FSGS) is January 13. A PDUFA date is the FDA's target date to make a decision on a drug application. If approved, Filspari would be the first treatment for FSGS, and the company says it is well-positioned for a commercial launch.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp premarket decline, retail sentiment on Stocktwits changed to ‘extremely bullish’ from ‘bullish’ a day back, accompanied by ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/TVTX_jpg_74da780cfd.webp" alt="TVTX.jpg">One user said that the FDA’s request is ‘very common’.<stembedurl>https://stocktwits.com/BIOTECH_GURU/message/641602359</stembedurl>However, one bearish user was skeptical about the timelines.<stembedurl>https://stocktwits.com/Aawilliam2003/message/641609384</stembedurl><h2 class="st-heading-2">2026 Outlook</h2>Travere Therapeutics provided an update on its sales outlook for the fourth quarter and full year 2025. The company expects U.S. net product sales of about $127 million in the fourth quarter (Q4) and about $410 million for the full year, based on preliminary and unaudited results. Travere ended 2025 with around $323 million in cash, cash equivalents, and marketable securities.Clinically, the company plans to advance clinical evidence supporting FILSPARI as a foundational treatment for IgA nephropathy, also known as Berger's disease, a chronic kidney ailment. Its partner, Chugai Pharmaceutical, is expected to submit a New Drug Application (NDA) for Sparsentan in Japan next year.Meanwhile, the company is on track to restart Phase 3 HARMONY Study of Pegtibatinase in classical homocystinuria (HCU), a genetic metabolic disorder, in the first quarter of 2026 following manufacturing process improvements.The stock has seen significant buying interest over the past year, gaining nearly 90%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-nvts-stock-gaining-retail-attention-ai-power-play/cmUXcZPR44k">NVTS Stock Draws Retail Interest On AI Data Center Power Play</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did TVTX Stock Crash 30% In Pre-Market Today?

Shares of Travere Therapeutics Inc. (TVTX) slumped 30% in premarket trading on Tuesday after the company said the U.S. Food and Drug Administration (FDA) requested additional information to assess Filspari’s clinical benefit.

The U.S. Food and Drug Administration recently requested additional information to assess Filspari’s clinical benefit.

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.2% - Here's What Happened

Travere Therapeutics (NASDAQ:TVTX) Shares Down 6.2% - Time to Sell...

Travere Therapeutics Provides Corporate Update and 2026 Outlook

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.04	--	--	N/A
Q3 '25	-$0.30	$0.28	192.20%	BEAT
Q2 '25	-$0.31	-$0.14	55.08%	BEAT
Q1 '25	-$0.57	-$0.47	17.11%	BEAT
Q4 '24	-$0.56	-$0.73	-29.89%	MISSED

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TVTX News

TVTXTravere Therapeutics Inc